4 days ago · EMBLAVEO TM is the first and only monobactam/β-lactamase inhibitor combination antibiotic therapy approved by the U.S. FDA to treat complicated intra-abdominal infections, including those caused by Gram-negative bacteria; Gram-negative bacterial infections represent a significant public health threat due to their ability to develop resistance to antimicrobial therapies

EMBLAVEO safely and effectively. See full prescribing information for EMBLAVEO. c EMBLAVEO (aztreonam and avibactam) for injection, for intravenous use Initial U.S. Approval: 2025 INDICATIONS AND USAGE EMBLAVEO is a combination of aztreonam, a monobactam antibacterial, and avibactam, a beta-lactamase inhibitor, that when used in

12 hours ago · The Food and Drug Administration (FDA) has approved Emblaveo™ (aztreonam and avibactam), in combination with metronidazole, for patients 18 years and older who have limited or no alternative options for the treatment of complicated intra-abdominal infections (cIAI), including those caused by the following susceptible Gram-negative microorganisms: …

3 days ago · AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and avibactam), as the first and only fixed-dose, intravenous,...

Mar 22, 2024 · Emblaveo is an antibiotic used in adults to treat: Complicated (difficult to treat) intra-abdominal (belly) infections; Hospital-acquired pneumonia (an infection of the lungs that is caught during a hospital stay), including ventilator-associated pneumonia (pneumonia that develops in patients who use a machine called a ventilator to help them ...

Apr 22, 2024 · EMBLAVEO ® is the first β-lactam/β-lactamase inhibitor antibiotic combination approved in the European Union for treating serious infections in adult patients caused by multidrug-resistant Gram-negative bacteria, including metallo-β-lactamase-producing bacteria

Aztreonam/avibactam, sold under the brand name Emblaveo (by Pfizer), is a combination of aztreonam, a β-lactam antibiotic, and avibactam, a β-Lactamase inhibitor, developed by AbbVie and Pfizer for aerobic Gram-negative infections.

Mar 22, 2024 · If approved, EMBLAVEO® will be indicated for the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP), complicated urinary tract infections (cUTI), including pyelonephritis, and infections due to aerobic Gram-negative organisms with ...

19 hours ago · Emblaveo is a combination of aztreonam, a monobactam antibiotic, and avibactam, a beta-lactamase inhibitor that can restore the ability of aztreonam to fight the types of bacteria than can become ...

3 days ago · Emblaveo (aztreonam and avibactam), is the first monobactam antiobiotic andbeta-lactamase inhibitor combination approved for this condition, according to a press release from AbbVie.